Targeting angiogenesis in myocardial infarction: Novel therapeutics (Review)

  • Authors:
    • Jiejie Li
    • Yuanyuan Zhao
    • Wei Zhu
  • View Affiliations

  • Published online on: November 22, 2021     https://doi.org/10.3892/etm.2021.10986
  • Article Number: 64
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Acute myocardial infarction (AMI) remains the main cause of mortality worldwide. Despite surgery and medical treatment, the non‑regeneration of dead cardiomyocytes and the limited contractile ability of scar tissue can lead to heart failure. Therefore, restoring blood flow in the infarcted area is important for the repair of myocardial injury. The objective of the present review was to summarize the factors influencing angiogenesis after AMI, and to describe the application of angiogenesis for cardiac repair. Collectively, this review may be helpful for relevant studies and to provide insight into future therapeutic applications in clinical practice.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li J, Zhao Y and Zhu W: Targeting angiogenesis in myocardial infarction: Novel therapeutics (Review). Exp Ther Med 23: 64, 2022
APA
Li, J., Zhao, Y., & Zhu, W. (2022). Targeting angiogenesis in myocardial infarction: Novel therapeutics (Review). Experimental and Therapeutic Medicine, 23, 64. https://doi.org/10.3892/etm.2021.10986
MLA
Li, J., Zhao, Y., Zhu, W."Targeting angiogenesis in myocardial infarction: Novel therapeutics (Review)". Experimental and Therapeutic Medicine 23.1 (2022): 64.
Chicago
Li, J., Zhao, Y., Zhu, W."Targeting angiogenesis in myocardial infarction: Novel therapeutics (Review)". Experimental and Therapeutic Medicine 23, no. 1 (2022): 64. https://doi.org/10.3892/etm.2021.10986